NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma
Agarwal, Gaurav Kazeroun, Mohammad Salazar, Mirian McBean, Khrystal Kannan, Ananya Larham, Jemma Varghese, Sherin Balik, Berrin Browning, Joseph Caulier, Alexis
Agarwal, Gaurav
Kazeroun, Mohammad
Salazar, Mirian
McBean, Khrystal
Kannan, Ananya
Larham, Jemma
Varghese, Sherin
Balik, Berrin
Browning, Joseph
Caulier, Alexis
Abstract
No abstract available
MIDER Authors
Affiliations
Boston Children's Hospital; Harvard Medical School; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University Hospitals Birmingham NHS Trust; University of Birmingham; University Hospital Southampton NHS Foundation Trust; University College London Hospitals NHS Foundation Trust; Assistance Publique des Hopitaux de Paris; UniversitƩ Paris CitƩ; Sorbonne UniversitƩ; University Hospitals Bristol and Weston NHS Foundation Trust
Date
2025-08-26
Type
Article
Collections
Citation
Agarwal G, Kazeroun M, Salazar M, McBean K, Kannan A, Larham J, Varghese S, Balik B, Browning J, Caulier A, Chan YLT, Giles H, Jenner M, Kishore B, Pratt G, Rabin N, Robinson R, Talbot A, van de Wyngaert Z, Xu K, Moore S, Boyle E, Ansari-Pour N, Ramasamy K, Hamblin A, Thakurta A, Gooding S. NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma. Br J Haematol. 2025 Nov;207(5):2167-2172. doi: 10.1111/bjh.70111. Epub 2025 Aug 26.